Also trades as: LEXXW (NASDAQ) · $vol 0M
LEXX NASDAQ
Lexaria Bioscience Corp.
1W: -14.6%
1M: -78.8%
3M: -66.6%
YTD: -71.5%
1Y: -80.9%
3Y: -80.6%
5Y: -97.3%
$2.88
-0.21 (-6.80%)
Weekly Expected Move ±30.1%
$1
$2
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$706K
+52.0% ▲
5Y CAGR: +17.5%
Gross Profit
$587K
+53.2% ▲
5Y CAGR: +22.2%
Operating Income
-$12M
-104.3% ▼
Net Income
-$12M
-105.4% ▼
EPS (Diluted)
$-0.66
-40.4% ▼
EBITDA
-$12M
-105.8% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $723K | $255K | $226K | $464K | $706K |
| YoY Growth | +129.6% | -64.7% | -11.4% | +105.2% | +52.0% |
| Cost of Revenue | $175K | $72K | $32K | $5K | $119K |
| Gross Profit | $547K | $184K | $195K | $459K | $587K |
| Gross Margin | 75.7% | 71.9% | 86.1% | 99.0% | 83.2% |
| R&D Expenses | $1M | $2M | $4M | $2M | $8M |
| SG&A Expenses | $5M | $6M | $3M | $4M | $4M |
| Operating Expenses | $6M | $8M | $7M | $6M | $12M |
| Operating Income | -$6M | -$7M | -$7M | -$6M | -$12M |
| Operating Margin | -786.8% | -2591.7% | -2888.5% | -1239.2% | -1648.0% |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$4M | -$7M | -$7M | -$6M | -$12M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$4M | -$7M | -$7M | -$6M | -$12M |
| Net Margin | -557.2% | -2846.3% | -2946.4% | -1248.2% | -1686.0% |
| EPS (Diluted) | $-0.92 | $-1.24 | $-1.01 | $-0.47 | $-0.66 |
| EBITDA | -$6M | -$7M | -$6M | -$6M | -$12M |
| Shares Outstanding | 4M | 6M | 7M | 12M | 18M |